Video

Recommendations for Optimal HER2 Testing in Breast Cancer

For High-Definition, Click

In order to accurately interpret HER2 test results, Joyce A. O’Shaughnessy, MD, recommends following the ASCO/CAP guidelines, which were updated in October 2013. The revisions now indicate that tumors are HER2-positive by IHC if protein expression is greater than 3 in more than 10% of cells. Also, by ISH testing, tumors are HER2-positive if the HER2/CEP17 ratio is greater than 2 or the HER2 gene copy number is over 6. These revisions make the guidelines more helpful in the clinic and are based on evidence from clinical studies, notes O’Shaughnessy.

ISH and IHC assays should be used preferentially for detecting HER2 status, as opposed to RT-PCR or microarrays, Hope S. Rugo, MD, believes. In some situations, expression based tests may incorrectly identify a patients as HER2-positive or negative, resulting in patients not receiving the most effective therapy. Moreover, the utilization of HER2-targeted therapies results in an improvement in survival for patients with breast cancer, which makes detecting HER2 positivity even more important, notes Kimberly L. Blackwell, MD.

In addition to optimizing testing strategies for HER2-positive breast cancer, studies are examining the optimization of dosing. One such study, explains Denise A. Yardley, MD, is exploring a weekly schedule of T-DM1 plus pertuzumab. This study will add to the clinical trial data already anticipated in the first-line setting from the MARIANNE study, which is exploring T-DM1 plus or minus pertuzumab compared to trastuzumab plus a taxane for untreated patients with HER2-positive metastatic breast cancer.

Related Videos
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the sensitivity and specificity of Rapid Lung NGS for biomarker testing in NSCLC.